Expert Review of Pharmacoeconomics & Outcomes Research Downloaded from informahealthcare.com by Emory University on 08/07/15 For personal use only.
Drug Profile
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study Expert Rev. Pharmacoecon. Outcomes Res. 15(4), 579–589 (2015)
Alfredo Carrato1, Pilar Garcı´a2, Rafael Lopez3, Teresa Macarulla4, Fernando Rivera5, Javier Sastre6, Joana Gostkorzewicz7, Patricia Benedit7 and Ferran Perez-Alca´ntara*8 1 Hospital Universitario Ramon y Cajal, Madrid, Spain 2 Hospital General Universitario Gregorio Maran˜on, Madrid, Spain 3 Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain 4 Hospital Universitari Vall d’Hebron, Universitat Auto`noma de Barcelona, Barcelona, Spain 5 Hospital Universitario Marques de Valdecilla, Santander, Spain 6 Hospital Clı´nico San Carlos, Center affiliated to the Red Tema´tica de Investigacion Cooperativa (RD06/0020/0021). Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain 7 Celgene SL, Madrid, Spain 8 Oblikue Consulting SL, Barcelona, Spain *Author for correspondence: Tel.: +34 932 521 377 Fax: +34 937 379 984 [email protected]
informahealthcare.com
The PANCOSTABRAX study evaluated the cost–effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine (GEM) versus GEM alone in the treatment of patients with metastatic pancreatic cancer in Spain. Efficacy data were obtained from the MPACT study and were modeled to a lifetime horizon using a Markov model. The analysis was performed from the payer’s perspective. Use of resources and key assumptions of the analysis were validated by a panel of oncologists. The addition of nab-paclitaxel to GEM showed higher effectiveness results (0.156 additional quality adjusted life years) at a higher cost (e6,477), resulting in a cost per quality-adjusted life years gained of e41,519. The combination of nab-paclitaxel and GEM has been shown to be an effective and well-tolerated option for the treatment of metastatic pancreatic cancer and, in addition to becoming the new standard of care, could also be considered a cost-effective option. KEYWORDS: cancer . cost . nab-paclitaxel . pancreatic . Spain
Pancreatic cancer is a major health problem in Spain in both men and women, with a high mortality rate that has increased in recent years [1,2]. The prognosis of patients with pancreatic cancer is extremely poor, with a median overall survival (OS) that, until recently, was barely 6 months, and a 5-year OS of
Drug Profile
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study Expert Rev. Pharmacoecon. Outcomes Res. 15(4), 579–589 (2015)
Alfredo Carrato1, Pilar Garcı´a2, Rafael Lopez3, Teresa Macarulla4, Fernando Rivera5, Javier Sastre6, Joana Gostkorzewicz7, Patricia Benedit7 and Ferran Perez-Alca´ntara*8 1 Hospital Universitario Ramon y Cajal, Madrid, Spain 2 Hospital General Universitario Gregorio Maran˜on, Madrid, Spain 3 Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain 4 Hospital Universitari Vall d’Hebron, Universitat Auto`noma de Barcelona, Barcelona, Spain 5 Hospital Universitario Marques de Valdecilla, Santander, Spain 6 Hospital Clı´nico San Carlos, Center affiliated to the Red Tema´tica de Investigacion Cooperativa (RD06/0020/0021). Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain 7 Celgene SL, Madrid, Spain 8 Oblikue Consulting SL, Barcelona, Spain *Author for correspondence: Tel.: +34 932 521 377 Fax: +34 937 379 984 [email protected]
informahealthcare.com
The PANCOSTABRAX study evaluated the cost–effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine (GEM) versus GEM alone in the treatment of patients with metastatic pancreatic cancer in Spain. Efficacy data were obtained from the MPACT study and were modeled to a lifetime horizon using a Markov model. The analysis was performed from the payer’s perspective. Use of resources and key assumptions of the analysis were validated by a panel of oncologists. The addition of nab-paclitaxel to GEM showed higher effectiveness results (0.156 additional quality adjusted life years) at a higher cost (e6,477), resulting in a cost per quality-adjusted life years gained of e41,519. The combination of nab-paclitaxel and GEM has been shown to be an effective and well-tolerated option for the treatment of metastatic pancreatic cancer and, in addition to becoming the new standard of care, could also be considered a cost-effective option. KEYWORDS: cancer . cost . nab-paclitaxel . pancreatic . Spain
Pancreatic cancer is a major health problem in Spain in both men and women, with a high mortality rate that has increased in recent years [1,2]. The prognosis of patients with pancreatic cancer is extremely poor, with a median overall survival (OS) that, until recently, was barely 6 months, and a 5-year OS of
